Synonyms: CMX-001 | CMX001 | HDP-CDV | hexadecyloxypropyl cidofovir | Tembexa®
brincidofovir is an approved drug (FDA (2021))
Compound class:
Synthetic organic
Comment: Brincidofovir is an orally bioavailable, lipid-conjugated (to enhance cellular penetration) ester prodrug of the acyclic nucleoside monophosphate antiviral cidofovir. The active metabolite is cidofovir diphosphate, which disrupts viral DNA polymerase activity and viral DNA replication. Brincidofovir has been investigated for infections caused by several virus families, including cytomegalovirus (CMV), BK virus (BKV), adenoviruses (AdV) [1], HPV [4], and Epstein-Barr virus (EBV), as well as for smallpox (Variola) infections.
A molecular docking study has indicated that brincidofovir interacts with both host ACE2 and SARS-CoV-2 3C-like (main) protease [2]. Further studies would be required to validate brincidofovir as a potential therapy for SARS-CoV-2 infection. |
|
Bioactivity Comments |
Antiviral activity against infection by human cytomegalovirus (human herpesvirus 5) AD169 (in HFF cells) EC50 0.9 nM [5]. |